Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
- PMID: 17512720
- DOI: 10.1016/j.ejca.2007.03.021
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
Abstract
The aim of this article is to present updated guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC). Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of CRC. For patients with stage II or stage III CRC who may be candidates for either liver resection or systemic treatment should recurrence develop, CEA should be measured every 2-3 months for at least 3 years after diagnosis. Insufficient evidence exists to recommend routine use of tissue factors such as thymidylate synthase, microsatellite instability (MSI), p53, K-ras and deleted in colon cancer (DCC) for either determining prognosis or predicting response to therapy in patients with CRC. Microsatellite instability, however, may be used as a pre-screen for patients with suspected hereditary non-polyposis colorectal cancer. Faecal occult blood testing but not faecal DNA markers may be used to screen asymptomatic subjects 50 years or older for early CRC.
Similar articles
-
Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.BMC Cancer. 2006 Jun 5;6:150. doi: 10.1186/1471-2407-6-150. BMC Cancer. 2006. PMID: 16753067 Free PMC article.
-
Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.Ann Surg. 2007 Dec;246(6):1040-6. doi: 10.1097/SLA.0b013e318142d918. Ann Surg. 2007. PMID: 18043108
-
Tumor markers in staging and prognosis of colorectal carcinoma.Neoplasma. 2008;55(2):138-42. Neoplasma. 2008. PMID: 18237252
-
Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.Expert Rev Anticancer Ther. 2001 Aug;1(2):247-57. doi: 10.1586/14737140.1.2.247. Expert Rev Anticancer Ther. 2001. PMID: 12113030 Review.
-
[Serological markers of colorectal cancer].Ugeskr Laeger. 2005 Oct 31;167(44):4163-7. Ugeskr Laeger. 2005. PMID: 16266568 Review. Danish.
Cited by
-
Prognostic prediction model of colorectal cancer based on preoperative serum tumor markers.World J Gastrointest Surg. 2024 May 27;16(5):1344-1353. doi: 10.4240/wjgs.v16.i5.1344. World J Gastrointest Surg. 2024. PMID: 38817280 Free PMC article.
-
Evaluation of the value of combined detection of tumor markers CA724, carcinoembryonic antigen, CA242, and CA19-9 in gastric cancer.World J Gastrointest Oncol. 2024 May 15;16(5):1737-1744. doi: 10.4251/wjgo.v16.i5.1737. World J Gastrointest Oncol. 2024. PMID: 38764828 Free PMC article.
-
Presence of CD44v9-Expressing Cancer Stem Cells in Circulating Tumor Cells and Effects of Carcinoembryonic Antigen Levels on the Prognosis of Colorectal Cancer.Cancers (Basel). 2024 Apr 19;16(8):1556. doi: 10.3390/cancers16081556. Cancers (Basel). 2024. PMID: 38672639 Free PMC article.
-
Novel tumor marker index using carcinoembryonic antigen and carbohydrate antigen 19-9 is a significant prognostic factor for resectable colorectal cancer.Sci Rep. 2024 Feb 20;14(1):4192. doi: 10.1038/s41598-024-54917-w. Sci Rep. 2024. PMID: 38378762 Free PMC article.
-
Screening and surveillance for hereditary colorectal cancer.Intest Res. 2024 Apr;22(2):119-130. doi: 10.5217/ir.2023.00112. Epub 2024 Feb 6. Intest Res. 2024. PMID: 38311713 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous